Managing director of Dishman Pharmaceuticals, JR Vyas expects the topline growth to be 15% or even more going forward. He also added that the bottomline...
Dishman apos;s Managing Director JR Vyas expects its key clients Abbott's contribution to grow by 50%. He further expects some more product orders coming in...
Managing director of Dishman Pharma tells CNBC-TV18 that higher earnings from its contract revenue business is what led to the surge in third quarter profits....